

# Products Under Development

Product	Therapeutic Area	Stage	Dossier availability
Cantharidin	Molluscum Contagiosum	R&D	
Clascoterone	Acne, Alopecia	R&D	2023
Fluralaner	Anti-Parasitic	Under Evaluation	
Ganaxolone	Epilepsy, Postpartum Depression	R&D	2024
Glycopyronium Bromide Micronized	COPD	R&D	2023
Glycopyrrolate Tosylate	Anticholinergic, Hyperhidrosis	R&D	2023
Lotilaner	Anti-Parasitic	Under Evaluation	
Niraparib Tosylate Monohydrate	Antineoplastic	R&D	2024
Omecamtiv Mecarbil	Chronic Heart Failure	Under Evaluation	
Propofol	Sedation & Anesthesia	R&D	2024
Remimazolam	Sedation, Amnesia, Anesthesia	R&D	2023
R-Ketamine	Antidepressant	R&D	
Ruxolitinib Phosphate	Myelofibrosis, Polycythaemia vera, Graft-versus-host disease	R&D	2024
Sitagliptin HCl Sitagliptin Phosphate	Type II diabetes	R&D	2022
Sparsentan	Antihypertensive	R&D	2024
Tamoxifen Citrate (Ph.Eur, )USP	Oncology	R&D	2023
Tapinarof	Plaque Psoriasis	R&D	2023
Trofinetide	Rett syndrome	Under Evaluation	
Umeclidinium Bromide	COPD	Under Evaluation	
Vamorolone	Duchenne Muscular Dystrophy	Under Evaluation	
Varenicline	Smoking Cessation	R&D	2023

